A prognostic model based on tumor microenvironment and immune cell in colorectal cancer

References

• Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164. doi: 10.3322/caac.21601.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–2516. doi: 10.1093/annonc/mds236.
   PubMed Web of Science ®Google Scholar
• Cervantes A, Adam R, Rosello S, et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol. 2023;34(1):10–32. doi: 10.1093/annonc/mdu260.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70. doi: 10.1093/annonc/mdx738.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422. doi: 10.1093/annonc/mdw235.
   PubMed Web of Science ®Google Scholar
• Ge P, Wang W, Li L, et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomed Pharmacother. 2019;118:109228. doi: 10.1016/j.biopha.2019.109228.
   PubMed Web of Science ®Google Scholar
• Koido S, Ohkusa T, Homma S, et al. Immunotherapy for colorectal cancer. World J Gastroenterol. 2013;19(46):8531–8542. doi: 10.3748/wjg.v19.i46.8531.
   PubMed Web of Science ®Google Scholar
• Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479–1486. doi: 10.1093/annonc/mdz197.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage Colon cancers. Nat Med. 2020;26(4):566–576. doi: 10.1038/s41591-020-0805-8.
   PubMed Web of Science ®Google Scholar
• Sheih A, Voillet V, Hanafi LA, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat Commun. 2020;11(1):219. Published 2020 Jan 10. doi: 10.1038/s41467-019-13880-1.
   PubMed Web of Science ®Google Scholar
• Jahanafrooz Z, Mosafer J, Akbari M, Hashemzaei M, Mokhtarzadeh A, Baradaran B, et al. Colon cancer therapy by focusing on Colon cancer stem cells and their tumor microenvironment. J Cell Physiol. 2020;235(5):4153–4166. doi: 10.1002/jcp.29337.
   PubMed Web of Science ®Google Scholar
• Saleh R, Taha RZ, Toor SM, et al. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. Cancer Immunol Immunother. 2020;69(10):1989–1999. doi: 10.1007/s00262-020-02593-w.
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. Published 2017 Aug 23. doi: 10.3389/fphar.2017.00561.
   PubMed Web of Science ®Google Scholar
• De Felice F, Marchetti C, Palaia I, et al. Immune check-point in cervical cancer. Crit Rev Oncol Hematol. 2018;129:40–43. doi: 10.1016/j.critrevonc.2018.06.006.
   PubMed Web of Science ®Google Scholar
• Tang J, Kong D, Cui Q, et al. Prognostic genes of breast cancer identified by gene Co-expression network analysis. Front Oncol. 2018; Sep 118:374. doi: 10.3389/fonc.2018.00374.
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016; 44(8):e71–e71. doi: 10.1093/nar/gkv1507.
   PubMed Web of Science ®Google Scholar
• Ito K, Murphy D. Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):e79–16. doi: 10.1038/psp.2013.56.
   PubMedGoogle Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 2008;9(1):559. doi: 10.1186/1471-2105-9-559.
   PubMed Web of Science ®Google Scholar
• Assubaie FN, Moody GJ, Thomas JD. Guanidinium ion-selective electrodes based on dibenzo-27-crown-9 and tetraphenylborate. Analyst. 1988; 113(1):61–64. doi: 10.1039/an9881300061.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Valente M, Covre A, et al. Immunotherapy targeting immune checkpoint(s) in brain metastases. Cytokine Growth Factor Rev. 2017;36:33–38. doi: 10.1016/j.cytogfr.2017.07.002.
   PubMed Web of Science ®Google Scholar
• Mao Y, Feng Q, Zheng P, et al. Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. Int J Cancer. 2018;143(9):2271–2280. doi: 10.1002/ijc.31613.
   PubMed Web of Science ®Google Scholar
• Wei X-L, Luo X, Sheng H, et al. PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. J Transl Med. 2020;18(1):475. doi: 10.1186/s12967-020-02636-x.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020; 20(11):662–680. doi: 10.1038/s41568-020-0285-7.
   PubMed Web of Science ®Google Scholar
• Wu J, Li H, Xie H, et al. The malignant role of exosomes in the communication among colorectal cancer cell, macrophage and microbiome. arcinogenesis. 2019;40(5):601–610. doi: 10.1093/carcin/bgy138.
   PubMed Web of Science ®Google Scholar
• Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16–25. doi: 10.1038/s41416-018-0333-1.
   PubMed Web of Science ®Google Scholar
• Yan L-H, Liu X-L, Mo S-S, et al. OX40 as a novel target for the reversal of immune escape in colorectal cancer. Am J Transl Res. 2021;13(3):923–934. .
   PubMed Web of Science ®Google Scholar
• Lv X, Xu G. Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers. World J Gastrointest Oncol. 2021; 13(11):1648–1667. doi: 10.4251/wjgo.v13.i11.1648.
   PubMed Web of Science ®Google Scholar
• Kraehenbuehl L, Weng C-H, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37–50. doi: 10.1038/s41571-021-00552-7.
   PubMed Web of Science ®Google Scholar
• Harmon C, Robinson MW, Hand F, et al. Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis. Cancer Immunol Res. 2019;7(2):335–346. doi: 10.1158/2326-6066.CIR-18-0481.
   PubMed Web of Science ®Google Scholar
• D'Antongiovanni V, Fornai M, Pellegrini C, et al. The adenosine system at the crossroads of intestinal inflammation and neoplasia. Int J Mol Sci. 2020;21(14):5089. doi: 10.3390/ijms21145089.
   PubMed Web of Science ®Google Scholar
• Tolba MF. Revolutionizing the landscape of colorectal cancer treatment: the potential role of immune checkpoint inhibitors. Int J Cancer. 2020;147(11):2996–3006. doi: 10.1002/ijc.33056.
   PubMed Web of Science ®Google Scholar
• Westendorf AM, Skibbe K, Adamczyk A, et al. Hypoxia enhances immunosuppression by inhibiting CD4+ effector T cell function and promoting treg activity. Cell Physiol Biochem. 2017;41(4):1271–1284. doi: 10.1159/000464429.
   PubMedGoogle Scholar
• Liang W, Sun F, Zhao Y, et al. Identification of susceptibility modules and genes for cardiovascular disease in diabetic patients using WGCNA analysis. J Diabetes Res. 2020;2020:4178639–4178611. doi: 10.1155/2020/4178639.
   PubMed Web of Science ®Google Scholar
• Kamai T, Tomosugi N, Abe H, , et al. Increased serum hepcidin·25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. . BMC Cancer. 2009;9(1):270. doi: 10.1186/1471-2407-9-270.
   PubMedGoogle Scholar
• Gao Y, Yu X, Zhang F, et al. Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8. J Hepatobiliary Pancreat Sci. 2019;26(6):219–226. doi: 10.1002/jhbp.624.
   PubMed Web of Science ®Google Scholar
• Conrad C, Benzel J, Dorzweiler K, et al. ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance. Clin Sci (Lond). 2019;133(1):83–99. doi: 10.1042/CS20180906.
   PubMed Web of Science ®Google Scholar
• Puolakkainen P, Koski A, Vainionpää S, et al. Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Med Oncol. 2014;31(3):884. doi: 10.1007/s12032-014-9.
   PubMed Web of Science ®Google Scholar
• Jiang C, Zhang Y, Yu HF, et al. Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Tumour Biol. 2012;33(6):2167–2172. doi: 10.1007/s13277-012-0477-1.
   PubMedGoogle Scholar
• Valkovskaya N, Kayed H, Felix K, et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med. 2007;11(5):1162–1174. doi: 10.1111/j.1582-4934.2007.00082.x.
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 2004;10(24):8363–8370. doi: 10.1158/1078-0432.CCR-04-1436.
   PubMed Web of Science ®Google Scholar
• Yang Z, Bai Y, Huo L, et al. Expression of a disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer. 2014;14(1):568. doi: 10.1186/1471-2407-14-568.
   PubMedGoogle Scholar
• Li Z, Feng Y, Li P, et al. CD1B is a potential prognostic biomarker associated with tumor mutation burden and promotes antitumor immunity in lung adenocarcinoma. Int J Gen Med. 2022;15:3809–3826. doi: 10.2147/IJGM.S352851.
   PubMed Web of Science ®Google Scholar
• Harris MC, Gary HE, Cooper SK, et al. Establishment of CD1b-restricted immunity to lipid antigens in the pulmonary ­response to Mycobacterium tuberculosis infection. bioRxiv. 2023. doi: 10.1101/2023.05.23.541963.
   Google Scholar